AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02214719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EASI-IDM use
Description: EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
Study NCT01322971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500mg orally twice daily for seven days
Study NCT01398033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-coated balloon
Description: Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
Study NCT03666390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
Study NCT03666390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
Study NCT02476448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Used to distend the bladder for cystoscopic evaluation
Study NCT02476448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Description: Administered orally preoperatively and assessed during cystoscopy
Study NCT02476448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 10%
Description: Used to distend the bladder for cystoscopic evaluation
Study NCT02476448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Description: Administered intravenously and assessed during cystoscopy
Study NCT02645864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
Study NCT02645864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m\^2 i.v. q2w
Study NCT01468480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro Root MTA
Description: application of MTA in second group and 24 hour interval before restoration
Study NCT01468480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro Root MTA- single visit
Description: application of MTA in third group and 15 minute interval before restoration
Study NCT01468480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiCal
Description: application of Multical in forth group as a pulp dressing agent
Study NCT01468480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dycal
Description: application of Dycal in first group as a pulp dressing agent
Study NCT01758094 — intervention group
Intervention type: DRUG
Intervention: Sustanon 250 mg ampule (Testosterone esters)
Description: Drug used for treatment of hypogonadism
Study NCT01398033 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-coated balloon
Description: percutaneous transluminal angioplasty with a non-coated balloon
Study NCT04711213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Dose 2
Description: Dexamethasone ophthalmic suspension dose 2
Study NCT03901261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuro-imaging, Lumbar puncture
Description: Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
Study NCT00448916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Orally-administered pregabalin
Study NCT04311177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan; 25 mg daily; oral administration
Study NCT01196715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alpha
Description: Aranesp 500 mcg vials once every 2 weeks.
Study NCT04311177 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
Study NCT01866878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: equipment rehabilitation stereognosis
Study NCT01866878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Study NCT02559206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral, once daily
Study NCT02559206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral, once daily
Study NCT00539916 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular orange juice consumption
Description: 600 mL /day.
Study NCT00539916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular orange juice consumption
Description: 600 mL /day.
Study NCT04583111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
Study NCT04583111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulpiride
Description: Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
Study NCT02791971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SpeakOut
Description: SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~* Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~* Printed materials for recipients to keep and/or share with friends.~* Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~* Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic.
Study NCT02791971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Control Intervention
Description: The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
Study NCT03933423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home based phototherapy and referral
Description: CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
Study NCT02207595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB5857
Description: * Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use
Study NCT02207595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use
Study NCT01196715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: 300 mcg vials twice a week, 3-4 days apart
Study NCT01196715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Red Cell Transfusion
Description: Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
Study NCT03937193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: computerized tomography
Description: abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
Study NCT03359694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT group
Description: Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
Study NCT03359694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ET group
Description: Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
Study NCT03359694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX group
Description: Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
Study NCT04711213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 1
Description: Placebo suspension dose 1
Study NCT04711213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 2
Description: Placebo suspension dose 2
Study NCT01659502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-118
Description: TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
Study NCT04741334 — intervention group
Intervention type: DRUG
Intervention: direct anticoagulant
Description: exposure to direct anticoagulant
Study NCT04741334 — intervention group
Intervention type: DRUG
Intervention: antiplatelet drugs
Description: exposure to antiplatelet drugs
Study NCT01322971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally twice daily for seven days
Study NCT02904759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Study NCT01304758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial MRgFUS System
Description: Treatment with the ExAblate Transcranial MRgFUS System.
Study NCT04741334 — intervention group
Intervention type: DRUG
Intervention: Dicumarols
Description: exposure to dicumarols
Study NCT04452227 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
Study NCT01536119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coparenting Breastfeeding Support Intervention
Description: The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
Study NCT04486040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage
Description: Use of the suction drainage after hip revision arthroplasty
Study NCT04486040 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-drainage
Description: Patients without drainage after surgery
Study NCT03309267 — intervention group
Intervention type: PROCEDURE
Intervention: Intercostal block
Description: Intercostal block +patient controlled analgesia
Study NCT04133415 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice stereotactic body radiation therapy
Description: -As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
Study NCT04133415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
Study NCT03719014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross
Description: The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
Study NCT01594242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02202980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT02202980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily
Study NCT00775255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin 250 mg/5 mL powder for oral suspension
Study NCT00775255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin 250 mg/5 mL powder for oral suspension
Study NCT02202980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VOX
Description: 100 mg tablet administered orally once daily with food
Study NCT04729790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727
Description: oral FMT capsules
Study NCT04729790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRIM-DJ2727
Description: oral FMT capsules
Study NCT03309267 — intervention group
Intervention type: PROCEDURE
Intervention: Serratus anterior plane block
Description: Serratus anterior plane block+patient controlled analgesia
Study NCT03559270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT03508635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT125134
Description: Oral capsules
Study NCT03508635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo of CORT125134
Description: Placebo
Study NCT02096978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preparing the osteotomy to accept a standard implant device
Description: Preparing the osteotomy with one of two randomly assigned protocols
Study NCT02096978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preparing the osteotomy to accept a standard implant device
Description: Preparing the osteotomy with one of two randomly assigned protocols
Study NCT00570843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New PEG based artificial tear
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
Study NCT00570843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optive
Description: 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
Study NCT02904759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01600729 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: No intervention.
Study NCT02006017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence summary alone plus a recommendation
Study NCT02006017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence summary alone
Study NCT03876249 — intervention group
Intervention type: OTHER
Intervention: exposure to RSV
Description: No intervention will be given, children naturally exposed to RSV in their early life
Study NCT02620813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
Study NCT02620813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Subjects will take isotretinoin as prescribed by their dermatologist.
Study NCT01806116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Study NCT02615769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: focused information of spirometry in the invitation
Description: Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
Study NCT02615769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard invitation
Description: The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
Study NCT03508635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Active comparator
Study NCT03508635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Challenge agent
Study NCT03508635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Challenge agent
Study NCT02440516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early treatment group
Description: Physical- and occupational Therapy
Study NCT02440516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Late treatment group
Description: Waiting list - then Physical- and occupational Therapy
Study NCT02662088 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic-lavage
Study NCT04349631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
Study NCT04671537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preloading with crystalloid fluid
Description: crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
Study NCT00641784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Intravenous Magnesium 6 gram load, 3 grams/hr
Study NCT00641784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedlipine
Description: Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
Study NCT00484419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam HCl
Description: coleveselam tablets 625 mg; 6 tablets/day
Study NCT02979574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electro-Acupuncture (EA)
Description: Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
Study NCT02979574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Battle Field Acupuncture (BFA)
Description: Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
Study NCT02979574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wait List Control (WLC)
Description: After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
Study NCT00484419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone maleate
Description: rosiglitazone tablets 4mg
Study NCT00484419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate
Description: sitagliptin phosphate tablets 100mg/day
Study NCT00567437 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NT-pro-BNP levels
Description: pre- and post-exercise NT-pro-BNP levels